Journal article
Once‐daily fluticasone furoate 50 mcg in mild‐to‐moderate asthma: a 24‐week placebo‐controlled randomized trial
Abstract
BACKGROUND: Inhaled glucocorticosteroids (ICS) are the mainstay of treatment in asthma. Fluticasone furoate (FF) is a novel, once-daily ICS asthma therapy. This study investigated the efficacy and safety of FF 50 mcg in patients with mild-to-moderate persistent asthma.
METHODS: A 24-week, multicenter, randomized, placebo-controlled and active-controlled, double-blind, double-dummy, parallel-group phase III study. Three hundred and fifty-one …
Authors
Busse WW; Bateman ED; O'Byrne PM; Lötvall J; Woodcock A; Medley H; Forth R; Jacques L
Journal
Allergy, Vol. 69, No. 11, pp. 1522–1530
Publisher
Wiley
Publication Date
November 2014
DOI
10.1111/all.12480
ISSN
0001-5148